Kendall Law Group, led by former federal judge Joe Kendall, is investigating Clarient, Inc. (NASDAQ: CLRT) for shareholders in connection with the proposed acquisition of the company by GE Healthcare. The national securities firm’s investigation seeks to determine whether Clarient and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a Clarient shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at email@example.com. On October 22, 2010, the companies announced the definitive merger agreement under which Clarient would be acquired by GE Healthcare in a transaction valued at approximately $580 million. Under the terms of the agreement, Clarient stockholders will receive $5.00 in cash for each share of Clarient/CLRT common stock held. According to Thompson/First Call, at least one analyst has set a price target of $6.00 per share for Clarient stock. The firm believes the transaction may be undervaluing the company. Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.